VivoSeq
Cardiovascular

Hypertension

442

Pipeline Programs↗

102

Active Trials↗

127

Companies Involved↗

Hypertension is a highly competitive landscape with 442 programs across 127 companies. The most active players are E-Star BioTech, LLC, Arnatar Therapeutics, Inc., ADARx Pharmaceuticals, Inc.. 161 therapies are approved with 120 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

93/100

Pipeline Velocity

66/100

Mech. Concentration

9/100

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

E-Star BioTech, LLC

1 program

Phase 1A

Arnatar Therapeutics, Inc.

1 program

Phase 1A

ADARx Pharmaceuticals, Inc.

1 program

Phase 1A

Asklepion Pharmaceuticals, LLC

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1Ferring logo

Ferring

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical59

Caffeine

Hikma Pharmaceuticals LLC

Losartan Potassium

Merck & Co.

Sodium Nitroprusside

Watson Pharmaceuticals

Propranolol Hydrochloride

Mylan Pharmaceuticals Inc

Sotatercept

Merck & Co.

Phase 137

Sildenafil

Viatris Specialty LLC

Captopril

Standard Chem. & Pharm. Co., Ltd.

Diltiazem

Bausch Health Americas, Inc.

L-Citrulline

Asklepion Pharmaceuticals, LLC

Calcium

Eli Lilly

Phase 265

Bosentan

Johnson & Johnson

Melatonin

Neurim Pharmaceuticals Ltd.

Sodium Nitrite

Hope Pharmaceuticals

Sapropterin Dihydrochloride

BioMarin Pharmaceutical

Torsemide

Sarfez Pharmaceuticals, Inc.

Phase 3120

Nitroglycerin

Viatris Specialty LLC

Alcohol

Astellas

Fimasartan

Boryung Pharmaceutical Co., Ltd

Orforglipron

Eli Lilly

Nicardipine

Sun Pharma

Approved161

Nifedipine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Nebivolol

Vitae Pharmaceuticals Inc., an Allergan affiliate

Tirzepatide

Eli Lilly

Topiramate

Wim Janssens

Analysis

Modality Breakdown

97%

Small molecule

538 of 556 classified programs — the dominant modality here.

3%ALL OTHERSProtein / enzyme5<1%Peptide5<1%Vaccine3<1%Monoclonal antibody2<1%RNA therapy2<1%Cell therapy1<1%

Small molecule leads; the ring shows all 556 classified programs, each share of the total. Modality classified for 99% of 567 pipeline programs.

Analysis

Trial Status

726

clinical trials

Completed460 · 63%
Unknown status83 · 11%
Recruiting58 · 8%
Terminated55 · 8%
Withdrawn23 · 3%
Not yet recruiting23 · 3%
Other24 · 3%

Clinical Trials

Trial Activity

726 trials

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Recruiting·—·Phase 4·NCT05593055·75 enrolled
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
Recruiting·UUniversity of Florida·Phase 4·NCT06246396·120 enrolled
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
Recruiting·PProf. Dr. med. Ingo Eitel·Phase 3·NCT06804161·3,000 enrolled
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
Recruiting·VVanderbilt University Medical Center·N/A·NCT03312556·12 enrolled
Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
Recruiting·JJW Pharmaceutical·Phase 3·NCT06643130·162 enrolled
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT06952530·487 enrolled
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
Recruiting·MMedical College of Wisconsin·N/A·NCT06220721·618 enrolled
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
Recruiting·XXiyuan Hospital of China Academy of Chinese Medical Sciences·Phase 4·NCT06093932·100 enrolled
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
Recruiting·SShenzhen Ausa Pharmed Co.,Ltd·Phase 4·NCT04974138·32,000 enrolled
Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)
Recruiting·UUniversity of Sao Paulo·Phase 4·NCT07018557·150 enrolled
Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension
Recruiting·UUniversity of Kansas Medical Center·N/A·NCT06626113·60 enrolled
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Recruiting·EE-Star BioTech, LLC·Phase 2·NCT06343298·120 enrolled
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
Recruiting·SShenzhen Ausa Pharmed Co.,Ltd·Phase 4·NCT04974151·24,000 enrolled
Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
Recruiting·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·N/A·NCT06647888·12,000 enrolled
Endothelin-1 Receptor Blockade in Resistant Hypertension
Recruiting·UUniversity Hospital, Rouen·Phase 2·NCT04388124·24 enrolled
Page 1 of 49

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)